09.03.13
Aurora Spine Inc. has opened its new headquarters facility in Carlsbad, Calif. The 17,288-square foot building addresses Aurora Spine’s need to expand research & development, engineering, business development, sales, marketing, shipping and IT. The company, which focuses on minimally invasive, regenerative spinal implant technologies, also has an international office in Harrogate, England.
“This is an exciting time for Aurora Spine,” said Trent Northcutt, president and CEO for Aurora Spine. “We are thrilled to be part of San Diego County’s growing economy. Aurora’s new office space will allow us to increase our capabilities in key areas that align with our current and future growth plans. The new 17,288 square feet, space will allow us to expand our core teams to support the growth we are experiencing while giving us a dedicated facility to host customer briefings and research & development.”
Aurora Spine recently received CE mark approval for its ZIP MIS interspinous fusion system for commercialization and sale in the European Union. The device is meant to be used in the non-cervical spine, and is intended to achieve supplemental fusion, along with bone graft material, for degenerative disc disease, spondylolisthesis, trauma (i.e., fracture or dislocation), and/or spinal tumors.
“This is an exciting time for Aurora Spine,” said Trent Northcutt, president and CEO for Aurora Spine. “We are thrilled to be part of San Diego County’s growing economy. Aurora’s new office space will allow us to increase our capabilities in key areas that align with our current and future growth plans. The new 17,288 square feet, space will allow us to expand our core teams to support the growth we are experiencing while giving us a dedicated facility to host customer briefings and research & development.”
Aurora Spine recently received CE mark approval for its ZIP MIS interspinous fusion system for commercialization and sale in the European Union. The device is meant to be used in the non-cervical spine, and is intended to achieve supplemental fusion, along with bone graft material, for degenerative disc disease, spondylolisthesis, trauma (i.e., fracture or dislocation), and/or spinal tumors.